Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1
Open accessThe DOI matches its Crossref record.
Abstract
We followed 145 men with chronic hepatitis B virus (HBV) hepatitis for 10 years to determine whether exposure to aflatoxin, or concomitant exposure to hepatitis C virus (HCV), or family history of hepatocellular carcinoma (HCC) increased the risk of developing HCC. We collected 8 monthly urine samples before beginning follow-up and pooled them to detect aflatoxin metabolite M1 (AFM1). AFM1 was detected in 78 (54%) of the subjects. The risk of HCC was increased 3.3-fold (with a 95% confidence interval of 1.2-8.7) in those with detectable AFM1 (above 3.6 ng/L). This relative risk was adjusted for age and for HCV status. The attributable risk from exposure to detectable AFM1 was 0.553 (0.087, 0.94). The relative risk of fatal cirrhosis for those with elevated AFM1 was 2.8 (0.6, 14.3), and the odds of having a persistently elevated alanine transaminase (ALT) were 2.5-fold greater in those with detectable AFM1 (P= .007). Concomitant infection with HCV increased the risk of HCC 5.8-fold (2.0-17), adjusted for age and AFM1 status. A family history of HCC increased the risk of HCC 5.6-fold, adjusted for age and AFM1. Four men with detectable AFM1 and HCC all had missense mutation in codon 249 of the p53 gene in cancer tissues. This study shows that exposure to AFM1 can account for a substantial part of the risk of HCC in men with chronic HBV hepatitis and adds importantly to the evidence that HCV and family history of HCC increase the risk of HCC in men with chronic HBV hepatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Rushing, B. R., & Selim, M. I. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.11.047 · Cited by 989
Mycotoxins and human disease: a largely ignored global health issue
Wild, C. P., & Gong, Y. Y. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp264 · Cited by 981
Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology
Kensler, T. W., Roebuck, B. D., Wogan, G. N., & Groopman, J. D. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq283 · Cited by 703
“Thus, aflatoxin exposure detected by the presence of the biomarker in urine can account for a substantial portion of HCC risk in men with chronic HBV hepatitis (Sun et al., 1999).”
BackgroundEnvironmental and chemical carcinogenesis
Wogan, G. N., Hecht, S. S., Felton, J. S., Conney, A. H., & Loeb, L. A. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.010 · Cited by 656
Aflatoxin B1 and M1: Biological Properties and Their Involvement in Cancer Development
Marchese, S., Polo, A., Ariano, A., Velotto, S., Costantini, S., & Severino, L. (2018) · Toxins · doi:10.3390/toxins10060214 · Cited by 594
Public Health Impacts of Foodborne Mycotoxins
Wu, F., Groopman, J. D., & Pestka, J. J. (2014) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-030713-092431 · Cited by 582
Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors
Schütte, K., Bornschein, J., & Malfertheiner, P. (2009) · Digestive Diseases · doi:10.1159/000218339 · Cited by 441
Abdelmalek, M. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02691-0 · Cited by 439
Viral hepatitis and liver cancer: the case of hepatitis C
Levrero, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209562 · Cited by 404
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394
Hepatocellular Carcinoma-Cause, Treatment and Metastasis
Tang, Z.-Y. (2001) · World Journal of Gastroenterology · doi:10.3748/wjg.v7.i4.445 · Cited by 375
International trends and patterns of primary liver cancer
McGlynn, K. A., Tsao, L., Hsing, A. W., Devesa, S. S., & Fraumeni, J. F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1456 · Cited by 349
Hepatocellular carcinoma: Recent trends in Japan
Kiyosawa, K., Umemura, T., Ichijo, T., Matsumoto, A., Yoshizawa, K., Gad, A., & Tanaka, E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.012 · Cited by 308
Tanaka, M., Katayama, F., Kato, H., Tanaka, H., Wang, J., Qiao, Y. L., & Inoue, M. (2011) · Journal of Epidemiology · doi:10.2188/jea.je20100190 · Cited by 304
Self-citationSynergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis
Kew, M. C. (2003) · Liver International · doi:10.1111/j.1478-3231.2003.00869.x · Cited by 302
V. Mitochondrial dysfunction in steatohepatitis
Pessayre, D., Mansouri, A., & Fromenty, B. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00426.2001 · Cited by 291
Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer
Lee, Y.-C. A., Cohet, C., Yang, Y.-C., Stayner, L., Hashibe, M., & Straif, K. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp280 · Cited by 254
Abdel-Rahman, O., Helbling, D., Schöb, O., Eltobgy, M., Mohamed, H., Schmidt, J., giryes, A., Mehrabi, A., Iype, S., John, H., et al. (2017) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12270 · Cited by 118
Metadata
- Authors
- Sun, Z., Lu, P., Gail, M. H., Pee, D., Zhang, Q., Ming, L., Wang, J., Wu, Y., Liu, G., Wu, Y., & Zhu, Y.
- Venue
- Hepatology
- Published
- 1999-08
- Volume
- 30
- Issue
- 2
- Pages
- 379-383
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2082914322
- Cited by
- 220
- References
- 0
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.